Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Custom Biomarker Assay Validation for Companion Diagnostic (CDx) Development in Basel

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Custom Biomarker Assay Validation for Companion Diagnostic (CDx) Development in Basel

Custom Biomarker Assay Validation for Companion Diagnostic (CDx) Development

CELL & GENE | RNA | BIOLOGICS

What is the typical validation scope for a CDx biomarker assay under GxP?

A GxP-compliant validation for a companion diagnostic assay encompasses a rigorous assessment of performance characteristics. This includes establishing accuracy, precision (intra-assay and inter-assay), specificity, sensitivity (Limit of Detection, LOD; Limit of Quantitation, LOQ), linearity, range, and robustness according to ICH, FDA, and EMA guidelines.

How do you ensure assay specificity for complex biological matrices?

Specificity is confirmed through multiple orthogonal methods. We evaluate potential cross-reactivity with structurally similar molecules and assess interference from endogenous substances within the target matrix (e.g., plasma, CSF, tissue homogenate). This may involve spike-and-recovery experiments and analysis of matrix blanks from a diverse population.

Which technology platforms are available for protein expression and biomarker quantification?

Our bioanalytical laboratory is platform-agnostic to best suit the analyte and context-of-use. We routinely validate custom assays on platforms including standard ELISA, high-sensitivity Luminex multiplex arrays, Meso Scale Discovery (MSD), and flow cytometry for cell-based biomarker analysis.

Can you support assay transfer from a discovery environment to a GxP-compliant setting?

Yes. We specialize in the formal development and validation of research-use-only (RUO) assays for GxP deployment. The process involves a gap analysis of the existing method, re-optimization using qualified key reagents, and full analytical validation to support clinical sample analysis.

The successful development of a companion diagnostic (CDx) requires a bioanalytical assay that is scientifically sound and rigorously validated for its intended clinical purpose. For sponsors, navigating the path from a promising discovery-phase biomarker to a robust, GxP-compliant diagnostic tool presents a significant technical hurdle. Franklin Biolabs provides custom biomarker assay development and validation services designed to meet these specific regulatory and scientific demands, ensuring data integrity for patient stratification and therapeutic monitoring.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

The Validation Framework for Precision Medicine

A companion diagnostic’s utility is directly dependent on the performance of its underlying bioanalytical method. The objective is to develop an assay that reliably and reproducibly measures a specific biomarker to inform therapeutic decisions. This requires a multi-stage validation process that characterizes every aspect of assay performance.

Our approach includes:

  • Analyte Characterization: Defining the specific form of the biomarker to be measured (e.g., total protein, phosphorylated isoform, cleaved fragment).

  • Reagent Qualification: Sourcing and qualifying key reagents, such as antibodies and calibrators, to ensure long-term consistency.

  • Method Optimization: Systematically refining assay parameters (e.g., incubation times, buffer composition, antibody concentrations) to achieve optimal sensitivity and specificity.

  • Formal Validation: Executing a pre-defined validation protocol to document assay performance against regulatory expectations.

From Novel Biomarker to Clinical Endpoint

The strategic value of a validated biomarker is exemplified by research into neuropathic mucopolysaccharidoses (MPS). A key study (PMID: 28934395) identified elevated spermine in cerebrospinal fluid (CSF) as a specific biomarker for neuropathic forms of the disease. The research demonstrated that spermine levels decreased following therapeutic intervention, linking the biomarker directly to treatment response.

This finding underscores the need for a validated assay capable of accurately quantifying CSF spermine. Such an assay becomes the tool that translates a scientific discovery into a clinical endpoint, enabling sponsors to:

  • Confirm a therapeutic’s mechanism of action.

  • Monitor treatment efficacy in real time.

  • Potentially stratify patient populations for clinical trials.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

GxP-Compliant Bioanalysis for Regulatory Submission

Our >100,000 sq ft facility is equipped to support your entire preclinical program. The data generated from a validated CDx assay is a core component of the regulatory submission package. Our teams have contributed to a 100% IND success rate for our partners’ programs since 2019, a track record of quality we continue under the Franklin Biolabs brand, which launched in 2024. We deliver GxP-compliant data packages structured to support an 18-24 month IND timeline, providing the analytical foundation required by global regulatory bodies, including the EMA and FDA. Our process is designed for transparency and collaboration, ensuring alignment with global regulatory standards.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities